TitusBen
☆    

2024-10-17 07:40
(204 d 20:54 ago)

Posting: # 24235
Views: 2,528
 

 PK Sampling Time Points - SR Formulation [Design Issues]

Hello all,

This is my 1st post here and excited to learn/share science.

I just want to share and ask your suggestions.

My study - I am carrying out Virtual BE studies for a SR-formulations and comparing its PK endpoints (Cmax, AUC).

Doubt - I am confused or doubting my manually chose PK sampling time points.

Drug X - Tmax - 8.40hr

Therefore, I chose 12 time points (aligns with US regulatory guideline) - 1, 3, 5, 6, 7, 7.5, 8, 8.5, 9, 10, 16, and 24 hrs which covers that absorption, distribution and elimination phase of the compound.


Any suggestions here to capture the PK profile the drug much better?

Thanks,
Titus
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2024-10-17 12:56
(204 d 15:39 ago)

@ TitusBen
Posting: # 24236
Views: 2,059
 

 PK Sampling Time Points - SR Formulation

Hi Titus!

❝ This is my 1st post here and excited to learn/share science.

Welcome to the club.

My study - I am carrying out Virtual BE studies for a SR-formulations and comparing its PK endpoints (Cmax, AUC).

Doubt - I am confused or doubting my manually chose PK sampling time points.

❝ Drug X - Tmax - 8.40hr

❝ Therefore, I chose 12 time points (aligns with US regulatory guideline) - 1, 3, 5, 6, 7, 7.5, 8, 8.5, 9, 10, 16, and 24 hrs which covers that absorption, distribution and elimination phase of the compound.

❝ Any suggestions here to capture the PK profile the drug much better?

In BE we are interested in assessing potential differences between formulations. With SR likely you crossed the Rubicon of flip-flop PK \(\small{(k_\text{a}\le k_\text{e})}\). Thus, what you see in the late part of the profile represents absorption (not elimination). The extent of absorption of SR formulations has to be primarily assessed based on AUC0–∞ (not on AUC0–t). 12 time points are probably too few – esp. in the late part of the profile – in order to obtain a reliable estimate of λz because you need at least three time points where the profile is log-linear.

Do you know more about the drug than its tmax? Further, tmax = 8.4 h is not set in stone. Profiles of SR formulations are sometimes pretty flat. Cmax is a composite PK metric (depends not only on \(\small{k_\text{a}}\) but also on \(\small{k_\text{e}}\) and \(\small{f}\)) and therefore, a poor predictor of \(\small{k_\text{a}}\). Since \(\small{k_\text{a}}\) varies between subjects, I would add more sampling time points around the anticipated tmax.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
TitusBen
☆    

2024-10-18 08:24
(203 d 20:11 ago)

@ Helmut
Posting: # 24237
Views: 1,967
 

 PK Sampling Time Points - SR Formulation

Dear Helmut!

❝ ❝ This is my 1st post here and excited to learn/share science.

❝ Welcome to the club.

Thank you very much for your kind welcome.

❝ Do you know more about the drug than its tmax? Further, tmax = 8.4 h is not set in stone. Profiles of SR formulations are sometimes pretty flat. Cmax is a composite PK metric (depends not only on \(\small{k_\text{a}}\) but also on \(\small{k_\text{e}}\) and \(\small{f}\)) and therefore, a poor predictor of \(\small{k_\text{a}}\). Since \(\small{k_\text{a}}\) varies between subjects, I would add more sampling time points around the anticipated tmax.


About the Drug - Since the study is a simulation-based experiment, I developed a hypothetical drug which is expected to have more colonic absorption to support my theoretical objective.

I have pasted the Log-Conc profile of the drug for your reference below.

[image]I totally agree with you point regarding Cmax. But also I want to be realistic in PK sampling time points to clinical setting. I mean, no over-sampling. therefore, according to US FDA guidance "Bio­equivalence Studies With Pharmacokinetic End­points for Drugs Submitted Under an ANDA Guidance for Industry, 2021", I can go upto 18 time points.

In my case, I do not see flip-flop kinetics, therefore I will assume the Tmax = 8.4 h as reliable parameter and add further more (3-5) time points.

I also would like to know, what are the criteria to choose the PK sampling time points as best as possible to capture the PK estimates well? (All I know to describe the ADE phase and at least three or more terminal elimination half-lives of the drug).

Kindly correct me if I am wrong in my assumptions.

Thanks a lot and open for comments!

Best Regards,
Titus
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2024-10-18 11:16
(203 d 17:19 ago)

@ TitusBen
Posting: # 24238
Views: 1,957
 

 PK Sampling Time Points - DR Formulation

Hi Titus,

❝ ❝ Do you know more about the drug than its tmax?

About the Drug - Since the study is a simulation-based experiment, I developed a hypothetical drug which is expected to have more colonic absorption to support my theoretical objective.

❝ I have pasted the Log-Conc profile of the drug for your reference below.

In your original post you talked about an SR formulation. Locally applied, locally acting drugs (LALAs) are delayed release (DR). The correct model is simple (one or two compartments but with a substantial lag-time), which is not your current one.
For an example see the profile of mesalazine (scroll down to Fig. 5 because what’s given in the NDA is crap).

❝ I totally agree with you point regarding Cmax. But also I want to be realistic in PK sampling time points to clinical setting. I mean, no over-sampling. therefore, according to US FDA guidance "Bio­equivalence Studies With Pharmacokinetic End­points for Drugs Submitted Under an ANDA Guidance for Industry, 2021", I can go upto 18 time points.

Guidelines are based on science in principle. :-D
However, they try to cover most of the ‘common’ cases, which might not be yours. For my approach see this presentation (slides 7–9). Unfortunately, lag-times in LALAs are terribly variable and you have to take that into account (in my simulations I use a truncated normal distribution and discretize it for the sampling times). See the [image]-script at the end.

Not a LALA but a PPI with extremely variable lag-times. Due to the acid-sensitivity of PPIs, all formulations are gastric resistant coated. Here the variability is caused by physiology (gastric motility / emptying) and is not a property of the formulation. Do you see how difficult it is to ‘catch’ Cmax?

❝ In my case, I do not see flip-flop kinetics, therefore I will assume the Tmax = 8.4 h as reliable parameter and add further more (3-5) time points.

Forget what I wrote about flip-flop PK. Anyhow, do you know that \(\small{k_\text{a}\gg k_\text{e}}\) (e.g., from IV or an IR formulation)?

❝ I also would like to know, what are the criteria to choose the PK sampling time points as best as possible to capture the PK estimates well? (All I know to describe the ADE phase and at least three or more terminal elimination half-lives of the drug).

My approach (if I have some real data beforehand):
  • Find a suitable PK model.
  • Define different sampling schedules.
  • With the parameters of the model, simulate the schedules.
  • Inspect the variance inflation factors (the lower is better).
  • Inspect plots of partial derivatives of parameters vs. time (optimal are sampling times close to the minima). See also this post for an example.


library(truncnorm)
roundClosest <- function(x, y) {     # Round x to the closest multiple of y
  return(y * round(x / y))
}
npSummary <- function(x) {           # Nonparametric summary of x
  y                <- summary(x)[-4] # remove the mean
  attr(y, "names") <- c("Min", "Q I", "Median", "Q III", "Max")
  return(y)
}
delta    <- 1                        # sampling every hour
tlag.exp <- 6                        # expected lag-time
tlag.min <- 2                        # fast gastric passage
tlag.max <- 72                       # maximum possible gastric passage
tlag.sd  <- 4                        # standard deviation (pretty large)
n        <- 1e3                      # number of simulations
set.seed(123456)                     # for reproducibility
tlag     <- rtruncnorm(n = n, a = tlag.min, b = tlag.max,
                       mean = tlag.exp, sd = tlag.sd) # continuous
tlag     <- roundClosest(tlag, delta)                 # discrete
npSummary(tlag)
hist(tlag, breaks = "FD", freq = FALSE, , xlim = c(0, npSummary(tlag)[["Max"]]),
     main = "", las = 1, xlab = expression(italic(t)[lag]))

Gives

Min    Q I Median  Q III    Max
  2      5      7      9     18


Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
TitusBen
☆    

2024-10-18 18:45
(203 d 09:49 ago)

@ Helmut
Posting: # 24241
Views: 1,890
 

 PK Sampling Time Points - DR Formulation

Dear Helmut,

Thanks for your kind response and the clarification. I appreciate it. It helped me to focus more!

❝ In your original post you talked about an SR formulation. Locally applied, locally acting drugs (LALAs) are delayed release (DR). The correct model is simple (one or two compartments but with a substantial lag-time), which is not your current one.


Yes, I agree. Since the drug has major fraction absorbed in colon, I assumed it to be a SR formulation. But clearly in the plot, there is no significant lag time.

I believe, lag-time can be only observed in normal Conc-time plot. Isn't?

Thanks,
Titus
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2024-10-19 10:20
(202 d 18:15 ago)

@ TitusBen
Posting: # 24242
Views: 1,849
 

 lag-time – another round

Hi Titus,

❝ But clearly in the plot, there is no significant lag time.

You wrote the model without one…

❝ I believe, lag-time can be only observed in normal Conc-time plot. Isn't?

Depends on what you mean by ‘observe’.
By convention in NCA BQLs before tmax are set to zero. Of course, 0 cannot be shown in a log-linear plot. By another convention, tlag is defined as the time point before the first measurable concentration. Obviously that’s not correct (see also there). The true one is a little later. Another approach1 is not implemented in any software; roll out your own code. Of course, you can estimate tlag by a PK model.2


  1. Csizmadia F, Endrényi L. Model-Independent Estimation of Lag Times with First-Order Absorption and Dis­po­sition. J Pharm Sci. 1998; 87(5): 608–12. doi:10.1021/js9703333
  2. In all exponential functions substitute \(\small{t}\) by \(\small{(t-t_\text{lag})}\) with the fitting constraint \(\small{t_\text{lag}\ge 0}\).

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
123 visitors (0 registered, 123 guests [including 5 identified bots]).
Forum time: 04:35 CEST (Europe/Vienna)

We should not speak so that it is possible
for the audience to understand us,
but so that it is impossible
for them to misunderstand us.    Quintilian

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5